הכנסות חזויות של החברה: NLS Pharmaceutics Ltd. (NLSP)
Geopolitical tensions and sanctions are hindering global therapy trials, which is reflected in the dynamics of NLS Pharmaceutics AG (NLSP) future sales revenues, where the indicator value is 0.00. NLS Pharmaceutics AG (NLSP) is developing unique non-hormonal ADHD treatments protected by patents for its molecule release system. Orphan drug status from the FDA and partnerships with somnology centers ensure a steady patient inflow for Mazindol.
פילוחי נתונים אנליטיים מרוכזים עבור nlspharma.com (NLSP)
Professional investors select resilient assets by analyzing future cash flow dynamics. This metric measures expected revenue, adjusting forecasts daily between official reports to assess credit risks. The current value of 0.00 regarding the prospective revenue of NLS Pharmaceutics AG (NLSP) confirms market expectations. The indicator's growth reflects the commercialization potential of mazindol for the therapy of hypersomnia. Future insurance payouts for the treatment of cognitive disorders guarantee the stability of this metric.
